Research Sample bioBank
Can’t find what you’re looking for? Contact us.
Or, need help ordering? 805.528.4341
Get Weekly Research Sample Updates in your Inbox:
Hepatitis C (HCV) Genotype 5 Clinical Research Samples
Discovery Life Sciences provides the highest quality Hepatitis C (HCV) Genotype 5 Clinical Research Samples and Residual Diagnostic Specimens from the Life Science Industry’s only convenient online, open access Biobank.
- All Hepatitis C (HCV) Genotype 5 Sample Orders are Packaged for Delivery within 24 Hours.
- All Specimens Ethically Obtained, De-Identified and provided with Highly Annotated Demographic and Clinical Data.
- Select from an HHS/OHRP Compliant Biorepository following ISBER/BBRB Guidelines.
- Packaged in Compliance with all UN Regulations (6.2) and U.S. DOT Hazmat regulations.
Advanced Data View:
Showing 27 of 27 total samples
Buy | Product ID | Sample | Origin | Matrix | Vial (ml) | Quantity | Price | Age | Gender | Ethnicity | Storage Temp | Sample Date | Test 1 | Test Data 1 | Detail 1 | Test 2 | Test Data 2 | Detail 2 | Product Details | Price | Buy | Blood Type | Co-morbidities | Symptoms | 3-series HepB Vaccine | Is Subject on Anti-Viral Therapy / Treatment | Acquired Infection Category | Additional Testing | HCV Date of Diagnosis | Current Anti-Viral Treatment or Therapies | Fibroscan | Co-Infections |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BBP0000-AO900388056081418D3 | Hepatitis C (HCV) Genotype 5 | South Africa | Plasma | 1.00 | $250.00 | 36 Y | Female | Non-Hispanic | <-70C | 14-Aug-18 | Roche COBAS AmpliPrep TaqMan | 3,425,000 | 14-Aug-18 | NS5B Sequence | 5 | Genotype | $250.00 | Unknown | Hep C and HIV | HIV Date of onset 2008 | No symptoms | No | No | U/A | ALT: 81 U/L | AST: 54 U/L | ALP: 111 U/L | Bilirubin: 101 umol/L | Serum Creatinine: 58 umol/L 14-Aug-18 | 2018-07-24 | None | F2 14-Aug-18 | |||||
| BBP0000-AO900388056081418D4 | Hepatitis C (HCV) Genotype 5 | South Africa | Plasma | 2.00 | 4.00 | $250.00 | 36 Y | Female | Non-Hispanic | <-70C | 14-Aug-18 | Roche COBAS AmpliPrep TaqMan | 3,425,000 | 14-Aug-18 | NS5B Sequence | 5 | Genotype | $250.00 | Unknown | Hep C and HIV | HIV Date of onset 2008 | No symptoms | No | No | U/A | ALT: 81 U/L | AST: 54 U/L | ALP: 111 U/L | Bilirubin: 101 umol/L | Serum Creatinine: 58 umol/L 14-Aug-18 | 2018-07-24 | None | F2 14-Aug-18 | ||||
| BBP0000-AO900388068070518D1 | Hepatitis C (HCV) Genotype 5 | South Africa | Plasma | 4.00 | 4.00 | $250.00 | 68 Y | Female | Non-Hispanic | <-70C | 05-Jul-18 | Roche COBAS AmpliPrep TaqMan | 4,970,000 | 2-Jul-19 | NS5B Blast | 5 | Genotype | $250.00 | Unknown | Hepatitis C | Decreased appetite, Fatigue, Sleep disturbances, Cirrhosis | No | No | Transfusion | ALT: 37 U/L | AST: 30 U/L | ALP: 82 U/L | Bilirubin: 7 umol/L | Serum Creatinine: 91 umol/L 4-Jul-19 | 2018-05-15 | None | 69 kPa | F4 2-Jul-19 | ||||
| BBP0000-AO900388068070518D3 | Hepatitis C (HCV) Genotype 5 | South Africa | Plasma | 1.00 | $250.00 | 68 Y | Female | Non-Hispanic | <-70C | 05-Jul-18 | Roche COBAS AmpliPrep TaqMan | 4,970,000 | 2-Jul-19 | NS5B Blast | 5 | Genotype | $250.00 | Unknown | Hepatitis C | Decreased appetite, Fatigue, Sleep disturbances, Cirrhosis | No | No | Transfusion | ALT: 37 U/L | AST: 30 U/L | ALP: 82 U/L | Bilirubin: 7 umol/L | Serum Creatinine: 91 umol/L 4-Jul-19 | 2018-05-15 | None | 69 kPa | F4 2-Jul-19 | |||||
| BBS0000-AO900388047122819DD | Hepatitis C (HCV) Genotype 5 | South Africa | Serum | 2.00 | 3.00 | $250.00 | 72 Y | Female | Non-Hispanic | <-70C | 28-Dec-19 | Roche COBAS AmpliPrep TaqMan | 1,128,600 | 4-Nov-19 | NS5B Blast | 5 | Genotype | $250.00 | Unknown | Hepatitis C | Abdominal pain, Fatigue | No | No | Transfusion | ALT: 36 U/L | AST: 38 U/L | ALP: 79 U/L | Bilirubin: 5 umol/L | Serum Creatinine: 49 umol/L 4-Nov-19 | 2019-11-04 | None | 6.2 kPa 4-Nov-19 | ||||
| BBS0000-AO900388048102219D1 | Hepatitis C (HCV) Genotype 5 | South Africa | Serum | 1.00 | $250.00 | 70 Y | Female | Non-Hispanic | <-70C | 22-Oct-19 | Xpert Cepheid | 766,000 | 22-Sep-19 | NS5B Blast | 5 | Genotype | $250.00 | Unknown | Hepatitis C | No symptoms | No | No | Transfusion | ALT: 38 U/L | AST: 39 U/L | ALP: 98 U/L | Bilirubin: 17 umol/L | Serum Creatinine: 46 umol/L 22-Sep-19 | 2019-10-22 | None | 8.9 kPa | F2 22-Oct-19 | |||||
| BBS0000-AO900388048102219D2 | Hepatitis C (HCV) Genotype 5 | South Africa | Serum | 2.00 | 4.00 | $250.00 | 70 Y | Female | Non-Hispanic | <-70C | 22-Oct-19 | Xpert Cepheid | 766,000 | 22-Sep-19 | NS5B Blast | 5 | Genotype | $250.00 | Unknown | Hepatitis C | No symptoms | No | No | Transfusion | ALT: 38 U/L | AST: 39 U/L | ALP: 98 U/L | Bilirubin: 17 umol/L | Serum Creatinine: 46 umol/L 22-Sep-19 | 2019-10-22 | None | 8.9 kPa | F2 22-Oct-19 | ||||
| BBS0000-AO900388048102219D3 | Hepatitis C (HCV) Genotype 5 | South Africa | Serum | 1.00 | $250.00 | 70 Y | Female | Non-Hispanic | <-70C | 22-Oct-19 | Xpert Cepheid | 766,000 | 22-Sep-19 | NS5B Blast | 5 | Genotype | $250.00 | Unknown | Hepatitis C | No symptoms | No | No | Transfusion | ALT: 38 U/L | AST: 39 U/L | ALP: 98 U/L | Bilirubin: 17 umol/L | Serum Creatinine: 46 umol/L 22-Sep-19 | 2019-10-22 | None | 8.9 kPa | F2 22-Oct-19 | |||||
| BBS0000-AO900388049090718D2 | Hepatitis C (HCV) Genotype 5 | South Africa | Serum | 2.50 | 3.00 | $250.00 | 65 Y | Female | Unknown | <-70C | 07-Sep-18 | Xpert Cepheid | 951,000 | 31-Jul-18 | NS5B Blast | 5 | Genotype | $250.00 | Unknown | Chronic Hep C and HIV | HIV Date of onset 4-Nov-2015. | Fatigue | No | No | U/A | ALT: 91 U/L | AST: 106 U/L | ALP: 197 U/L | Bilirubin: 7 umol/L | Serum Creatinine: 34 umol/L 16-Aug-19 | 2018-07-31 | None | F1 7-Sep-18 | ||||
| BBS0000-AO900388049090718D3 | Hepatitis C (HCV) Genotype 5 | South Africa | Serum | 1.00 | $250.00 | 65 Y | Female | Unknown | <-70C | 07-Sep-18 | Xpert Cepheid | 951,000 | 31-Jul-18 | NS5B Blast | 5 | Genotype | $250.00 | Unknown | Chronic Hep C and HIV | HIV Date of onset 4-Nov-2015. | Fatigue | No | No | U/A | ALT: 91 U/L | AST: 106 U/L | ALP: 197 U/L | Bilirubin: 7 umol/L | Serum Creatinine: 34 umol/L 16-Aug-19 | 2018-07-31 | None | F1 7-Sep-18 | |||||
| BBS0000-AO900388049090718D4 | Hepatitis C (HCV) Genotype 5 | South Africa | Serum | 1.00 | $250.00 | 65 Y | Female | Unknown | <-70C | 07-Sep-18 | Xpert Cepheid | 951,000 | 31-Jul-18 | NS5B Blast | 5 | Genotype | $250.00 | Unknown | Chronic Hep C and HIV | HIV Date of onset 4-Nov-2015. | Fatigue | No | No | U/A | ALT: 91 U/L | AST: 106 U/L | ALP: 197 U/L | Bilirubin: 7 umol/L | Serum Creatinine: 34 umol/L 16-Aug-19 | 2018-07-31 | None | F1 7-Sep-18 | |||||
| BBS0000-AO900388052112718D2 | Hepatitis C (HCV) Genotype 5 | South Africa | Serum | 2.00 | 4.00 | $250.00 | 41 Y | Female | Unknown | <-70C | 27-Nov-18 | Xpert Cepheid | 1,000,000 | 28-Aug-18 | Innogenetics Versant HCV | 5 | Genotype | $250.00 | Unknown | Chronic Hepatitis C | No symptoms | No | No | U/A | ALT: 19 U/L | AST: 17 U/L | ALP: 152 U/L | Bilirubin: 6 umol/L | Serum Creatinine: 59 umol/L 20-Nov-18 | 2018-08-28 | None | F1 27-Nov-18 | ||||
| BBS0000-AO900388052112718D3 | Hepatitis C (HCV) Genotype 5 | South Africa | Serum | 1.00 | $250.00 | 41 Y | Female | Unknown | <-70C | 27-Nov-18 | Xpert Cepheid | 1,000,000 | 28-Aug-18 | Innogenetics Versant HCV | 5 | Genotype | $250.00 | Unknown | Chronic Hepatitis C | No symptoms | No | No | U/A | ALT: 19 U/L | AST: 17 U/L | ALP: 152 U/L | Bilirubin: 6 umol/L | Serum Creatinine: 59 umol/L 20-Nov-18 | 2018-08-28 | None | F1 27-Nov-18 | |||||
| BBS0000-AO900388052112718D4 | Hepatitis C (HCV) Genotype 5 | South Africa | Serum | 1.00 | $250.00 | 41 Y | Female | Unknown | <-70C | 27-Nov-18 | Xpert Cepheid | 1,000,000 | 28-Aug-18 | Innogenetics Versant HCV | 5 | Genotype | $250.00 | Unknown | Chronic Hepatitis C | No symptoms | No | No | U/A | ALT: 19 U/L | AST: 17 U/L | ALP: 152 U/L | Bilirubin: 6 umol/L | Serum Creatinine: 59 umol/L 20-Nov-18 | 2018-08-28 | None | F1 27-Nov-18 | |||||
| BBS0000-AO900388065090319D1 | Hepatitis C (HCV) Genotype 5 | South Africa | Serum | 3.00 | 4.00 | $250.00 | 54 Y | Female | Non-Hispanic | <-70C | 03-Sep-19 | Xpert Cepheid | 113,000 | 6-Aug-19 | NS5B Blast | 5 | Genotype | $250.00 | Unknown | Hepatitis C | Fatigue | No | No | Transfusion | ALT: 37 U/L | AST: 3 U/L | ALP: 120 U/L | Bilirubin: 8 umol/L | Serum Creatinine: 62 umol/L 6-Aug-19 | 2019-08-06 | None | F4 6-Aug-19 | ||||
| BBS0000-AO900388065090319D2 | Hepatitis C (HCV) Genotype 5 | South Africa | Serum | 1.00 | $250.00 | 54 Y | Female | Non-Hispanic | <-70C | 03-Sep-19 | Xpert Cepheid | 113,000 | 6-Aug-19 | NS5B Blast | 5 | Genotype | $250.00 | Unknown | Hepatitis C | Fatigue | No | No | Transfusion | ALT: 37 U/L | AST: 3 U/L | ALP: 120 U/L | Bilirubin: 8 umol/L | Serum Creatinine: 62 umol/L 6-Aug-19 | 2019-08-06 | None | F4 6-Aug-19 | |||||
| BBS0000-AO900388065090319D3 | Hepatitis C (HCV) Genotype 5 | South Africa | Serum | 1.00 | $250.00 | 54 Y | Female | Non-Hispanic | <-70C | 03-Sep-19 | Xpert Cepheid | 113,000 | 6-Aug-19 | NS5B Blast | 5 | Genotype | $250.00 | Unknown | Hepatitis C | Fatigue | No | No | Transfusion | ALT: 37 U/L | AST: 3 U/L | ALP: 120 U/L | Bilirubin: 8 umol/L | Serum Creatinine: 62 umol/L 6-Aug-19 | 2019-08-06 | None | F4 6-Aug-19 | |||||
| BBS0000-AO900388066071718D2 | Hepatitis C (HCV) Genotype 5 | South Africa | Serum | 1.00 | $250.00 | 60 Y | Male | Non-Hispanic | <-70C | 17-Jul-18 | Xpert Cepheid | 12,700 | 17-Jul-18 | NS5B Sequence | 5 | Genotype | $250.00 | Unknown | Chronic Hepatitis C | No symptoms | No | No | U/A | ALT: 54 U/L | AST: 40 U/L | ALP: 94 U/L | Bilirubin: 5 umol/L | Serum Creatinine: 40 umol/L 17-Jul-18 | 2017-11-08 | None | 7.6 kPa | F1 F2 17-Jul-18 | |||||
| BBS0000-AO900388066071718D4 | Hepatitis C (HCV) Genotype 5 | South Africa | Serum | 1.00 | $250.00 | 60 Y | Male | Non-Hispanic | <-70C | 17-Jul-18 | Xpert Cepheid | 12,700 | 17-Jul-18 | NS5B Sequence | 5 | Genotype | $250.00 | Unknown | Chronic Hepatitis C | No symptoms | No | No | U/A | ALT: 54 U/L | AST: 40 U/L | ALP: 94 U/L | Bilirubin: 5 umol/L | Serum Creatinine: 40 umol/L 17-Jul-18 | 2017-11-08 | None | 7.6 kPa | F1 F2 17-Jul-18 | |||||
| BBS0000-AO900388067031219D1 | Hepatitis C (HCV) Genotype 5 | South Africa | Serum | 3.00 | 4.00 | $250.00 | 39 Y | Male | Non-Hispanic | <-70C | 12-Mar-19 | Xpert Cepheid | 437,197 | 12-Mar-19 | NS5B Blast | 5 | Genotype | $250.00 | Unknown | Hepatitis C | No symptoms | No | No | U/A | ALT: 80 U/L | AST: 37 U/L | ALP: 87 U/L | Bilirubin: 10 umol/L | Serum Creatinine: 89 umol/L 12-Mar-19 | 2019-03-12 | None | F1 14-Mar-19 | ||||
| BBS0000-AO900388067031219D2 | Hepatitis C (HCV) Genotype 5 | South Africa | Serum | 1.00 | $250.00 | 39 Y | Male | Non-Hispanic | <-70C | 12-Mar-19 | Xpert Cepheid | 437,197 | 12-Mar-19 | NS5B Blast | 5 | Genotype | $250.00 | Unknown | Hepatitis C | No symptoms | No | No | U/A | ALT: 80 U/L | AST: 37 U/L | ALP: 87 U/L | Bilirubin: 10 umol/L | Serum Creatinine: 89 umol/L 12-Mar-19 | 2019-03-12 | None | F1 14-Mar-19 | |||||
| BBS0000-AO900388067031219D3 | Hepatitis C (HCV) Genotype 5 | South Africa | Serum | 1.00 | $250.00 | 39 Y | Male | Non-Hispanic | <-70C | 12-Mar-19 | Xpert Cepheid | 437,197 | 12-Mar-19 | NS5B Blast | 5 | Genotype | $250.00 | Unknown | Hepatitis C | No symptoms | No | No | U/A | ALT: 80 U/L | AST: 37 U/L | ALP: 87 U/L | Bilirubin: 10 umol/L | Serum Creatinine: 89 umol/L 12-Mar-19 | 2019-03-12 | None | F1 14-Mar-19 | |||||
| BBS0000-AO900388069070918DD | Hepatitis C (HCV) Genotype 5 | South Africa | Serum | 4.00 | 4.00 | $250.00 | 61 Y | Female | Non-Hispanic | <-70C | 09-Jul-18 | Roche COBAS AmpliPrep TaqMan | 11,200 | 26-Jun-18 | NS5B Sequence | 5 | Genotype | $250.00 | Unknown | Hepatitis C | Joint pain | No | No | Transfusion | ALT: 33 U/L | AST: 45 U/L | ALP: 107 U/L | Bilirubin: 8 umol/L | Serum Creatinine: 82 umol/L 26-Jun-18 | 2018-06-26 | None | F4 | Cirrhosis 9-Jul-18 | ||||
| BBS0000-AO900388070071619D2 | Hepatitis C (HCV) Genotype 5 | South Africa | Serum | 1.00 | $250.00 | 61 Y | Male | Non-Hispanic | <-70C | 16-Jul-19 | Xpert Cepheid | 102,000 | 16-Jul-19 | NS5B Blast | 5 | Genotype | $250.00 | Unknown | Hepatitis C | No symptoms | Yes | No | Transfusion Hemophilia | ALT: 38 U/L | AST: 32 U/L | ALP: 75 U/L | Bilirubin: 11 umol/L | Serum Creatinine: 104 umol/L 2-Jul-19 | 2019-07-02 | None | 48 kPa | F4 16-Jul-19 | |||||
| BBS0000-AO900388070071619D3 | Hepatitis C (HCV) Genotype 5 | South Africa | Serum | 1.00 | $250.00 | 61 Y | Male | Non-Hispanic | <-70C | 16-Jul-19 | Xpert Cepheid | 102,000 | 16-Jul-19 | NS5B Blast | 5 | Genotype | $250.00 | Unknown | Hepatitis C | No symptoms | Yes | No | Transfusion Hemophilia | ALT: 38 U/L | AST: 32 U/L | ALP: 75 U/L | Bilirubin: 11 umol/L | Serum Creatinine: 104 umol/L 2-Jul-19 | 2019-07-02 | None | 48 kPa | F4 16-Jul-19 | |||||
| BBS0000-AO900388070071619D4 | Hepatitis C (HCV) Genotype 5 | South Africa | Serum | 3.00 | 4.00 | $250.00 | 61 Y | Male | Non-Hispanic | <-70C | 16-Jul-19 | Xpert Cepheid | 102,000 | 16-Jul-19 | NS5B Blast | 5 | Genotype | $250.00 | Unknown | Hepatitis C | No symptoms | Yes | No | Transfusion Hemophilia | ALT: 38 U/L | AST: 32 U/L | ALP: 75 U/L | Bilirubin: 11 umol/L | Serum Creatinine: 104 umol/L 2-Jul-19 | 2019-07-02 | None | 48 kPa | F4 16-Jul-19 | ||||
| BBS0005-AO900079163082217DD | Hepatitis C (HCV) Genotype 5 | Serum | 1.00 | 4.00 | $250.00 | 62 Y | Female | Unknown | <-70C | 22-Aug-17 | Roche | 1,838 IU/mL | Viral Load | Siemens Versant Lipa | 5 | Genotype | $250.00 | Unknown | Fatigue | No | No | Transfusion | ALT: 17 U/L | AST: 23 U/L | ALP: 87 | Bilirubin: 8 umol/L | Serum Creatinine: | 58 umol/L | Fibroscan F2 | 17-Aug-17 | 22-Mar-17 | Hepatitis C |
Keep in mind that all the samples comprised in the Research Sample Biobank represent only a small number of the clinical research specimens available through our Discovery Partners™ clinical research programs. If you can’t find the specific sample type, specimen or biofluids you are looking for please make sure to call our client services group at 805.528.4341 - and ask how we can help support your project from resources available at active clinical sites.
Please read carefully before purchasing:
Clinical specimens for research use only.
Transmissible Infectious Risk! May be HIV, HBV and HCV REACTIVE or of unknown infectious agent test status. Materials provided are derived from human blood, tissue and other bio-fluids. Handle all samples as if capable of transmitting infectious agents. Practice good laboratory technique and dispose of in properly marked medical waste.
If you need help searching for a LARGER SAMPLE SET with specific data elements, please contact our Client Services group who can format Excel spreadsheets for a comprehensive review of all available samples: USA (805) 528-4341
These products are supplied without warranty for suitability for specific applications or analytical determinations.
Specimens and data will be may be used for general biomarker research, assay and instrument validation purposes only. All Research products identified as “Diagnostic Remnant Samples” are human biological materials leftover from routine laboratory analysis and are de-identified (coded) to protect subject confidentiality. Under OHRP definition 45 CFR 46.102(f) these coded specimens are not considered subjects for Human research requiring informed consent. Specimens cannot be used for whole genomic sequencing of genetic material. Research products designated as “Clinical Research Samples” by “type” are obtained from IRB approved research study protocols with informed consent obtained from each subject enrolled. Specimens cannot be used for whole genomic sequencing of genetic material.